Corbus' CRB-913 Obesity Drug Hits 5% Weight Loss in Phase 1b, Beats Safety Bar
CRBP sits 25% above its 52-week low of $7.12 on elevated volume (4.8× avg).
Summary
Corbus announced positive topline data from its CANYON-1 Phase 1b trial of CRB-913, an oral CB1 inverse agonist for obesity. The 60 mg dose achieved 5% placebo-adjusted weight loss at 12 weeks, with statistically significant results across all doses and no plateauing. Safety profile appears favorable: fewer GI side effects than oral GLP-1s and no serious psychiatric events, addressing a key concern for this drug class. This is a major de-risking event for a $157M market cap company with a cash-burning pipeline. The company plans to engage the FDA and start a Phase 2 monotherapy study in H1 2027, with full data at ObesityWeek in November. This follows the recent CRB-701 FDA clearance and a $127.5M ATM program, but today's news is the first clinical proof-of-concept for CRB-913 in obesity.
At the time of this announcement, CRBP was trading at $8.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $157.1M. The 52-week trading range was $7.12 to $20.56. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.